MA35643B1 - Inhibiteur de cetp d'oxazolidinone bicyclique condensée - Google Patents

Inhibiteur de cetp d'oxazolidinone bicyclique condensée

Info

Publication number
MA35643B1
MA35643B1 MA37024A MA37024A MA35643B1 MA 35643 B1 MA35643 B1 MA 35643B1 MA 37024 A MA37024 A MA 37024A MA 37024 A MA37024 A MA 37024A MA 35643 B1 MA35643 B1 MA 35643B1
Authority
MA
Morocco
Prior art keywords
inhibitor
condensed bicyclic
cetp
bicyclic oxazolidinone
oxazolidinone cetp
Prior art date
Application number
MA37024A
Other languages
English (en)
Inventor
Pengcheng Patrick Shao
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA35643B1 publication Critical patent/MA35643B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés ayant la structure de formule i, comprenant des sels pharmaceutiquement acceptables des composés, qui sont des inhibiteurs de cetp et sont utiles pour élever le cholestérol-hdl, abaisser le cholestérol-ldl, et pour traiter ou prévenir l'athérosclérose.
MA37024A 2011-10-28 2014-05-13 Inhibiteur de cetp d'oxazolidinone bicyclique condensée MA35643B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552592P 2011-10-28 2011-10-28
PCT/US2012/061842 WO2013063217A1 (fr) 2011-10-28 2012-10-25 Inhibiteur de cetp d'oxazolidinone bicyclique condensée

Publications (1)

Publication Number Publication Date
MA35643B1 true MA35643B1 (fr) 2014-11-01

Family

ID=47143312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37024A MA35643B1 (fr) 2011-10-28 2014-05-13 Inhibiteur de cetp d'oxazolidinone bicyclique condensée

Country Status (41)

Country Link
US (2) US8871738B2 (fr)
EP (1) EP2771345B1 (fr)
JP (1) JP5658427B2 (fr)
KR (1) KR101686308B1 (fr)
CN (1) CN103958524B (fr)
AR (1) AR088565A1 (fr)
AU (1) AU2012328759B2 (fr)
BR (1) BR112014010204A2 (fr)
CA (1) CA2852743C (fr)
CL (1) CL2014001090A1 (fr)
CO (1) CO6940419A2 (fr)
CR (1) CR20140256A (fr)
CY (1) CY1118464T1 (fr)
DK (1) DK2771345T3 (fr)
DO (1) DOP2014000086A (fr)
EA (1) EA026123B1 (fr)
EC (1) ECSP14002458A (fr)
ES (1) ES2604953T3 (fr)
GE (1) GEP20166434B (fr)
HK (1) HK1195558A1 (fr)
HR (1) HRP20161541T1 (fr)
HU (1) HUE030568T2 (fr)
IL (1) IL232130A (fr)
IN (1) IN2014CN03073A (fr)
JO (1) JO3210B1 (fr)
LT (1) LT2771345T (fr)
MA (1) MA35643B1 (fr)
ME (1) ME02557B (fr)
MX (1) MX345222B (fr)
NI (1) NI201400034A (fr)
PE (1) PE20141230A1 (fr)
PL (1) PL2771345T3 (fr)
PT (1) PT2771345T (fr)
RS (1) RS55420B1 (fr)
SG (1) SG11201401884PA (fr)
SI (1) SI2771345T1 (fr)
TN (1) TN2014000158A1 (fr)
TW (1) TWI601731B (fr)
UA (1) UA114612C2 (fr)
WO (1) WO2013063217A1 (fr)
ZA (2) ZA201403091B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2012058187A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibiteur de cetp substitué par des amines cycliques à base d'oxazolidinone
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2934518B1 (fr) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Inhibiteurs de la cetp spirocycliques
WO2014099834A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Composés de thiazolidinone thérapeutiques
CN105143193B (zh) * 2013-01-31 2017-12-15 株式会社钟根堂 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9981970B2 (en) 2013-07-30 2018-05-29 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors
EP3038465B1 (fr) * 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Formulation pharmaceutique orale d'omarigliptine
WO2015054088A1 (fr) 2013-10-10 2015-04-16 Merck Sharp & Dohme Corp. Indolines 3,3'-disubstituées utilisées comme inhibiteurs de la protéine de transfert du cholestérol estérifié
EP3083642B1 (fr) * 2013-12-17 2018-09-05 Merck Sharp & Dohme Corp. Isoxazolines bicycliques condensées utilisées comme inhibiteurs de la protéine de transfert du cholestérol estérifié
AU2014381733B2 (en) 2014-02-05 2020-09-03 Newamsterdam Pharma B.V. Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
EP3174537B1 (fr) 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Isoxazolines monocycliques utilisées comme inhibiteurs de la protéine de transfert des esters de cholestérol
WO2016067194A1 (fr) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Procédé de préparation d'anacetrapib et d'un intermédiaire de celui-ci
KR20170087880A (ko) * 2014-11-28 2017-07-31 코와 가부시키가이샤 의약
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3307672A4 (fr) * 2015-06-12 2019-04-10 Rhodia Operations Nanoparticules hybrides contenant des dendrons, procédés de production de ces nanoparticules hybrides, et leurs utilisations
EP3322420B1 (fr) * 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Hétérocycles bicycliques en tant qu'inhibiteurs de la protéine de transfert des esters de cholestérol
ES2811845T3 (es) 2015-09-23 2021-03-15 Janssen Pharmaceutica Nv Heterociclos tricíclicos para el tratamiento del cáncer
BR112018005625B1 (pt) 2015-09-23 2023-11-14 Janssen Pharmaceutica N.V Compostos derivados de quinolina, piridopirazina, naftiridina e quinazolinona, composições farmacêuticas que os compreende e uso dos mesmos
CN106432053A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法
CN106432058A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种Niraparib中间体4‑（3S‑哌啶‑3‑基）苯胺的制备方法
CN111285894B (zh) * 2018-12-10 2021-03-05 北京天一绿甫医药科技有限公司 用于制备软海绵素类化合物的中间体及其制备方法
CN110639018B (zh) * 2019-11-14 2020-06-26 牡丹江医学院 一种防治老年性高血压的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
CA2415742A1 (fr) 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
CA2434491A1 (fr) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
WO2003011824A1 (fr) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Modulateurs bicycliques de la fonction du recepteur androgene
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
AU2003260085B2 (en) 2002-08-29 2008-09-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004066963A2 (fr) 2003-01-17 2004-08-12 Merck & Co., Inc. Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
AU2004249138B2 (en) * 2003-06-12 2008-07-17 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2005018638A1 (fr) 2003-08-13 2005-03-03 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CN1938320A (zh) * 2004-03-26 2007-03-28 伊莱利利公司 用于治疗异常脂肪血症的化合物和方法
JP4922924B2 (ja) 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害薬
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
CN101384590A (zh) * 2005-12-22 2009-03-11 先灵公司 作为凝血酶受体拮抗剂的唑并异喹啉
JP5199121B2 (ja) * 2005-12-30 2013-05-15 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤
AU2006335108B2 (en) 2005-12-30 2011-04-07 Merck Sharp & Dohme Corp. CETP inhibitors
EP2029560B1 (fr) 2005-12-30 2013-04-24 Merck Sharp & Dohme Corp. Derives de 1,3-oxazolidin-2-one en tant qu'inhibiteurs de cetp
WO2010039474A1 (fr) 2008-10-01 2010-04-08 Merck Sharp & Dohme Corp. Promédicaments d'inhibiteurs de cetp à base d'oxazolidinone
WO2011028395A1 (fr) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Inhibiteur de cetp à base de pyridyl oxazolidinone
WO2012058187A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibiteur de cetp substitué par des amines cycliques à base d'oxazolidinone
US9353101B2 (en) 2012-05-02 2016-05-31 Merck Sharp & Dohme Corp. Cyclic amine substituted heterocyclic CETP inhibitors

Also Published As

Publication number Publication date
EA201490889A1 (ru) 2015-05-29
ZA201406833B (en) 2016-02-24
TN2014000158A1 (en) 2015-09-30
ZA201403091B (en) 2015-04-29
HK1195558A1 (zh) 2014-11-14
CL2014001090A1 (es) 2014-08-01
IL232130A0 (en) 2014-05-28
IL232130A (en) 2017-07-31
ME02557B (fr) 2017-02-20
NI201400034A (es) 2014-10-10
CY1118464T1 (el) 2017-07-12
US20130109649A1 (en) 2013-05-02
WO2013063217A1 (fr) 2013-05-02
CA2852743A1 (fr) 2013-05-02
KR20140094571A (ko) 2014-07-30
CN103958524A (zh) 2014-07-30
JO3210B1 (ar) 2018-03-08
TWI601731B (zh) 2017-10-11
MX345222B (es) 2017-01-20
TW201321388A (zh) 2013-06-01
AR088565A1 (es) 2014-06-18
LT2771345T (lt) 2016-11-25
US20140378493A1 (en) 2014-12-25
EA026123B1 (ru) 2017-03-31
HRP20161541T1 (hr) 2016-12-30
CO6940419A2 (es) 2014-05-09
PE20141230A1 (es) 2014-09-28
UA114612C2 (uk) 2017-07-10
US9346825B2 (en) 2016-05-24
KR101686308B1 (ko) 2016-12-13
JP5658427B2 (ja) 2015-01-28
AU2012328759B2 (en) 2015-09-10
BR112014010204A2 (pt) 2017-05-09
AU2012328759A1 (en) 2014-05-01
RS55420B1 (sr) 2017-04-28
ECSP14002458A (es) 2015-11-30
JP2014532652A (ja) 2014-12-08
CR20140256A (es) 2014-07-15
SG11201401884PA (en) 2014-09-26
CA2852743C (fr) 2016-08-02
HUE030568T2 (en) 2017-05-29
PL2771345T3 (pl) 2017-04-28
SI2771345T1 (sl) 2016-12-30
DK2771345T3 (en) 2017-01-09
US8871738B2 (en) 2014-10-28
CN103958524B (zh) 2016-04-06
DOP2014000086A (es) 2014-07-15
EP2771345A1 (fr) 2014-09-03
ES2604953T3 (es) 2017-03-10
EP2771345B1 (fr) 2016-09-21
PT2771345T (pt) 2016-11-30
MX2014005074A (es) 2014-08-01
NZ625435A (en) 2015-12-24
IN2014CN03073A (fr) 2015-07-31
GEP20166434B (en) 2016-02-10

Similar Documents

Publication Publication Date Title
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MA38050B1 (fr) Inhibiteurs de gdf-8
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA201500362A1 (ru) Ингибиторы rho-киназы
MA33492B1 (fr) Inhibiteurs de bace
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX2009010057A (es) Compuesto de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de beta-secretasa.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
MA33304B1 (fr) Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
MX2012015098A (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
EP2595482A4 (fr) Inhibiteurs de l'aldostérone synthase
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine